DEA Unveils Lengthy-Overdue Particular Registration for Telemedicine in Proposed Rule

Within the remaining days of the Biden administration, the Drug Enforcement Administration (DEA) launched a proposed rule that might enable practitioners with a Particular Registration to prescribe Schedule III-V, and in restricted circumstances Schedule II, managed substances through telemedicine.

Practitioners with a Particular Registration would nonetheless have to receive a DEA registration in every state the place they prescribe or dispense managed substances. Nevertheless, the proposed rule establishes a restricted, cheaper State Telemedicine Registration as an alternative choice to the normal DEA registration. The proposed rule imposes a number of obligations on practitioners with Particular Registrations after they prescribe managed substances through telemedicine. Of word, practitioners would have to be situated in the identical state because the affected person on the time of the encounter when issuing a Schedule II managed substance prescription, and the typical month-to-month variety of Schedule II managed substances prescribed through telemedicine would have to be restricted to lower than 50% of the practitioner’s whole Schedule II prescriptions (together with each telemedicine prescriptions and non-telemedicine prescriptions).

If finalized, the Particular Registration course of would supply another pathway for practitioners to prescribe managed substances through telemedicine if the DEA telemedicine prescribing flexibilities presently in place via December 31, 2025, expire. We offer a abstract of a few of the key provisions of the proposed rule beneath.

Definitions

The proposed rule introduces a number of new definitions, a few of which embrace:

• Clinician practitioner — a person practitioner who supplies direct affected person care or assesses, diagnoses, or treats medical circumstances.
• Platform practitioner — a coated on-line telemedicine platform that dispenses managed substances by advantage of its central involvement as an middleman within the distant prescribing of managed substances by a person practitioner. Platform practitioners are topic to the necessities imposed upon non-pharmacist practitioners below the Managed Substances Act, 21 U.S.C. Sections 801-904, and its laws.
• Coated on-line telemedicine platform — an entity that facilitates connections between sufferers and clinician practitioners, through an audio-video telecommunications system, for the prognosis and therapy of sufferers which will consequence within the prescription of managed substances, however shouldn’t be a hospital, clinic, native in-person medical observe, or insurance coverage supplier, and meets a number of of the next standards:
  • The entity explicitly promotes or advertises the prescribing of managed substances via the platform;
  • The entity has monetary pursuits, whether or not direct incentives or in any other case, tied to the amount or varieties of managed substance prescriptions issued via the platform, together with however not restricted to, possession curiosity in pharmacies used to fill sufferers’ prescriptions, or rebates from these pharmacies;
  • The entity exerts management or affect on medical decision-making processes or prescribing associated to managed substances, together with, however not restricted to: prescribing tips or protocols for clinician practitioners employed or contracted by the platform; consideration of clinician practitioner prescribing charges within the entity’s hiring, retention, or compensation selections; imposing specific or de facto prescribing quotas; directing sufferers to most well-liked pharmacies; and/or
  • The entity has management or custody of the prescriptions or medical information of sufferers who’re prescribed managed substances via the platform.

Particular Registrations

Classes and Eligibility

The proposed rule establishes the next classes of Particular Registrations and eligibility necessities:

• Telemedicine Prescribing Registration: This registration would enable clinician practitioners to prescribe Schedule III-V managed substances.
  • Clinician practitioners would wish to show a legit want for the registration.
  • Physicians, nurse practitioners, physicians, and different mid-level practitioners outlined below 21 C.F.R. § 1300.01 (“mid-level practitioners”) would have a legit have to prescribe Schedule III-V managed substances in the event that they anticipate to deal with sufferers for whom in-person exams can be burdensome.
    • Examples embrace sufferers who expertise extreme climate circumstances, dwell in distant or distant areas, or have communicable illnesses.
• Superior Telemedicine Prescribing Registration: This registration would enable sure specialised clinician practitioners to prescribe Schedule II-V managed substances.
  • Specialised clinician practitioners would wish to show a legit want for the registration and justify the extra authorization to prescribe Schedule II drugs. These practitioners would wish to supply info demonstrating their specialised coaching on their Particular Registration software.
  • Specialised physicians and board-certified mid-level practitioners would have a legit have to prescribe Schedule II-V managed substances when treating susceptible affected person populations. This contains people who face important limitations to accessing care and that suffer from debilitating or terminal sicknesses.
  • Solely specialised physicians and board-certified mid-level practitioners within the following restricted circumstances or observe specialties are eligible:
    • Psychiatrists;
    • Hospice care physicians;
    • Palliative care physicians;
    • Practitioners rendering therapy at long-term care services;
    • Pediatricians;
    • Neurologists; and
    • Mid-level practitioners and physicians from different specialties who’re board licensed within the therapy of psychiatric or psychological issues, hospice care, palliative care, pediatric care, or neurological issues unrelated to the therapy and administration of ache.
• Telemedicine Platform Registration: This registration would enable coated on-line telemedicine platforms to dispense Schedule II-V managed substances via a clinician practitioner who holds a Telemedicine Prescribing Registration or Superior Telemedicine Prescribing Registration (i.e., a platform practitioner).
  • Coated on-line telemedicine platforms would wish to show a legit want for the registration.
  • Coated on-line telemedicine platforms, of their capability as platform practitioners, would have a legit have to dispense Schedule II-V managed substances after they:
    • Anticipate to supply mandatory providers that join sufferers with clinician practitioners through telemedicine for the prognosis, therapy, and prescription of managed substances;
    • Adjust to federal and state laws;
    • Oversee the clinician practitioner’s prescribing practices; and
    • Implement safeguards to prioritize affected person security and forestall diversion, abuse, or misuse of managed substances.
  • Platform practitioners would wish to attest to their legit want on their Particular Registration software.

Particular Registration numbers can be formatted distinctly, permitting pharmacists to simply differentiate between practitioners with a Particular Registration and people with a conventional DEA registration.

Software Necessities

Within the proposed rule, the DEA outlines a number of Particular Registration software necessities. Notably, candidates would wish to supply a bodily tackle as their registered location, and platform practitioners would wish to reveal all employment relationships, contractual relationships, {and professional} affiliations with any clinician practitioner with a Particular Registration and on-line pharmacy.

State Telemedicine Registration

Along with a Particular Registration, clinician practitioners and platform practitioners, except exempt, would nonetheless have to receive a DEA registration in every state wherein they intend to prescribe or dispense managed substances to sufferers through telemedicine. Nevertheless, in lieu of the normal DEA registration, the proposed rule establishes a restricted State Telemedicine Registration, which might be cheaper for clinician practitioners. The proposed charge is $50 for clinician practitioners, reflecting a big discount from the price of a conventional DEA registration, and $888 for platform practitioners, which matches the price of a conventional DEA registration. Just like Particular Registrations, State Telemedicine Registration numbers can be formatted distinctly, permitting pharmacists to simply differentiate between practitioners with a State Telemedicine Registration and people with a conventional DEA registration.

Necessities of the Proposed Rule

Telehealth Modality

Just like the remaining rule concerning telemedicine prescribing of buprenorphine, practitioners can be permitted to prescribe Schedule III-V managed substances accepted by the U.S. Meals & Drug Administration to deal with opioid use dysfunction through telemedicine (presently restricted to buprenorphine) via an audio-only go to. (See our dialogue on the DEA’s remaining buprenorphine rule right here.) Audio-only visits would solely be permitted if the practitioner has the aptitude to make use of audio-video, however the affected person is both unable to make use of video or doesn’t consent to it. Nevertheless, in contrast to the ultimate buprenorphine rule, therapy would have to be initiated via an audio-video go to, and the practitioner would wish to have carried out not less than one medical examination of the affected person through audio-video. Prescriptions not assembly the factors described above would solely be capable of be issued via an audio-video go to.

Schedule II Managed Substances

Practitioners would solely be permitted to prescribe Schedule II managed substances through telemedicine if they’re bodily situated in the identical state because the affected person on the time of the encounter when the prescription is issued. Moreover, the variety of Schedule II managed substances prescribed through telemedicine, averaged month-to-month, can be restricted to lower than 50% of the practitioner’s whole Schedule II prescriptions (together with each telemedicine prescriptions and non-telemedicine prescriptions).

PDMP Examine

Efficient instantly, if the proposed rule is finalized, practitioners with a Particular Registration would wish to test the affected person’s managed substance prescription information in Prescription Drug Monitoring Packages (PDMPs) of sure jurisdictions earlier than issuing a prescription for managed substances through telemedicine. The practitioner would wish to overview the PDMPs for any managed substance prescriptions issued to the affected person throughout the final 12 months, or, if lower than a 12 months is offered, for the complete out there interval. The related jurisdictions embrace:

• The state the place the affected person is situated;
• The state the place the practitioner is situated; and
• Any U.S. jurisdiction with PDMP reciprocity agreements with both of the states above.

Three years after the efficient date, earlier than issuing a prescription for managed substances through telemedicine, practitioners with a Particular Registration would wish to test the PDMPs of all U.S. jurisdictions for managed substance prescriptions issued to the affected person throughout the final 12 months, or, if lower than a 12 months is offered, for the complete out there interval. If there isn’t a means to carry out this nationwide PDMP test, the practitioner would proceed performing the PDMP checks as described above. We word that there’s presently no nationwide PDMP database in operation.

Extra Necessities and Commentary

The proposed rule additionally:

• Units forth sure recordkeeping, affected person identification verification, reporting, prescription, and e-prescribing necessities for these with Particular Registrations;
• Notes that practitioners with Particular Registrations would have to be situated throughout the U.S. when issuing a prescription through telemedicine and would wish to nonetheless adjust to any relevant state necessities and restrictions concerning prescribing managed substances;
• Emphasizes that after an in-person medical examination has been carried out, the practitioner and affected person would now not be thought-about to be engaged within the observe of telemedicine, and the necessities of the proposed rule wouldn’t apply; and
• Establishes reporting necessities for pharmacies filling Particular Registration prescriptions.

A Temporary Historical past

The rule stems from the Ryan Haight Act, which amended the Managed Substances Act to limit practitioners from prescribing managed substances except the practitioner conducts an in-person examination of the affected person. The Managed Substances Act additionally requires practitioners receive a separate DEA registration in every state the place their sufferers are situated. The Ryan Haight Act (at 21 U.S.C. § 802(54)) outlines seven exceptions below which practitioners might prescribe managed substances through telemedicine with out an in-person examination, one in every of which includes practitioners who’ve obtained a particular registration. Congress anticipated the DEA to challenge the particular registration rule shortly after the Ryan Haight Act was signed into regulation in 2008. After years of DEA failing to take action, Congress and the White Home signed the SUPPORT Act of 2018, a federal regulation that mandated DEA promulgate the particular registration rule by October 2019. 

Through the COVID-19 Public Well being Emergency (PHE), the DEA issued letters on March 25, 2020, and March 31, 2020, granting non permanent exceptions to the Ryan Haight Act and its implementing guidelines that enabled DEA-registered practitioners to prescribe managed substances with out an in-person examination and with a DEA registration in just one state. In March 2023, two months earlier than the top of the PHE, the DEA proposed a rule on telemedicine prescribing of managed substances, however the rule didn’t embrace a particular registration framework and was not favorably-viewed. In response, the DEA shortly rescinded the proposed rule and prolonged the COVID-era flexibilities in Might 2023 and once more in October 2023. In June 2024, the DEA submitted a particular registration rule for Workplace of Administration and Funds clearance that was so unworkable for stakeholders that it was not printed. As an alternative, the flexibilities have been additional prolonged in November 2024, and are actually set to run out on December 31, 2025. (For extra particulars, see our earlier discussions on the DEA’s proposed guidelines for telemedicine prescribing of managed substances and the first, second, and third non permanent guidelines extending COVID-era flexibilities.)

Make Your Voice Heard

The DEA is soliciting feedback till 11:59 p.m. ET March 18, 2025. Stakeholders might submit feedback electronically right here or through common or specific mail to the next tackle:

Drug Enforcement Administration
Attn: DEA Federal Register Consultant/DPW
8701 Morrissette Drive, Springfield, VA 22152

All correspondence, together with attachments, should embrace a reference to “Docket No. DEA-407”.

Moreover, these with considerations concerning the proposed rule can share their suggestions by contacting their native Congressperson or the White Home.

What Comes Subsequent

With the widespread frustration that met the March 2023 and June 2024 variations of this rule, there may be little likelihood that the proposed rule might be finalized near its present kind. A key level of rivalry for stakeholders within the proposed rule is the nationwide PDMP test requirement, which is seen as overly burdensome given the absence of a nationwide PDMP database — a burden the DEA continues to underestimate. Nevertheless, the way forward for the Particular Registration is unclear because of the change in administration and doubtlessly altering priorities and approaches.

President Trump’s first spherical of government orders included a regulatory freeze. Nevertheless, the Regulatory Freeze Pending Overview Govt Order doesn’t have an effect on the proposed rule. To affect the route of the proposed rule, ATA Motion has urged President Trump to prioritize the fast withdrawal of it. If the proposed rule undergoes one other set of revisions and spherical of notice-and-comment rulemaking, it’s unlikely that practitioners can have entry to a particular registration in 2025. With no particular registration course of this 12 months, one other extension of the DEA telemedicine flexibilities might be essential. We are going to proceed to intently monitor any developments concerning the particular registration course of.

For extra info on telemedicine, telehealth, digital care, distant affected person monitoring, digital well being, and different well being improvements, together with the group, publications, and consultant expertise, go to Foley’s Telemedicine & Digital Well being Business Group.